Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry

Jamie L. Todd 1,2*, Megan L. Neely 1,2, Robert Overton 1, Katey Durham 3, Mridu Gulati 4, Howard Huang 5, Jesse Roman 6, L. Kristin Newby 1,2,7, Kevin R. Flaherty 8, Richard Vinisko 3, Yi Liu 3, Janine Roy 9, Ramona Schmid 10, Benjamin Strobel 10, Christian Hesslinger 10, Thomas B. Leonard 3, Imre Noth 11, John A. Belperio 12†, Scott M. Palmer 1,2† and on behalf of the IPF-PRO Registry investigators

Abstract

Background: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease for which diagnosis and management remain challenging. Defining the circulating proteome in IPF may identify targets for biomarker development. We sought to quantify the circulating proteome in IPF, determine differential protein expression between subjects with IPF and controls, and examine relationships between protein expression and markers of disease severity.

Methods: This study involved 300 patients with IPF from the IPF-PRO Registry and 100 participants without known lung disease. Plasma collected at enrolment was analysed using aptamer-based proteomics (1305 proteins). Linear regression was used to determine differential protein expression between participants with IPF and controls and associations between protein expression and disease severity measures (percent predicted values for forced vital capacity [FVC] and diffusion capacity of the lung for carbon monoxide [DLco]; composite physiologic index [CPI]). Multivariable models were fit to select proteins that best distinguished IPF from controls.

Results: Five hundred fifty one proteins had significantly different levels between IPF and controls, of which 47 showed a |log2(fold-change)| > 0.585 (i.e. > 1.5-fold difference). Among the proteins with the greatest difference in levels in patients with IPF versus controls were the glycoproteins thrombospondin 1 and von Willebrand factor and immune-related proteins C-C motif chemokine ligand 17 and bactericidal permeability-increasing protein. Multivariable classification modelling identified nine proteins that, when considered together, distinguished IPF versus control status with high accuracy (area under receiver operating curve = 0.99). Among participants with IPF, 14 proteins were significantly associated with FVC % predicted, 23 with DLco % predicted, 14 with CPI. Four proteins (roundabout homolog-2, spondin-1, polymeric immunoglobulin receptor, intercellular adhesion molecule 5) demonstrated the expected relationship across all three disease severity measures. When considered in pathways analyses, proteins associated with the presence or severity of IPF were enriched in pathways involved in platelet and haemostatic responses, vascular or platelet derived growth factor signalling, immune activation, and extracellular matrix organisation.

(Continued on next page)
Background

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic interstitial lung disease of unknown cause [1]. Establishing a confident diagnosis of IPF remains a clinical challenge and relies on a multifaceted, multidisciplinary approach [1, 2]. Two anti-fibrotic drugs, nintedanib and pirfenidone, have been approved for the treatment of IPF and shown to slow the rate of lung function decline [3, 4]. However, the rate of disease progression in patients with IPF is variable, and there are no reliable predictors of disease progression or indicators of therapeutic response. The discovery and development of IPF-specific biomarkers for use as diagnostic adjuncts or measures of disease activity or treatment response remains a critical unmet need [5].

Most of the currently available clinical biomarkers are proteins. Proteomic profiling represents a highly translatable initiation point for biomarker discovery [6, 7]. Proteomics, the broad-scale, simultaneous quantification of a large number of proteins using high throughput technology, enables an understanding of the relationship between numerous potential protein biomarkers and disease-specific parameters. The results of such studies can be validated using targeted approaches such as enzyme-linked immunosorbent assays (ELISAs) where such assays exist. Given their relative methodological ease, protein-based assays are often more readily implemented in the clinical laboratory than other molecular assays.

Prior proteomics work has suggested that patients with IPF have a unique peripheral blood proteome [8, 9]. A study using aptamer-based methods showed that, compared with healthy controls, the blood of patients with IPF was enriched in proteins related to platelet activation and coagulation responses, complement activation, and cardiac muscle hypertrophy, while proteins related to host defence were under-represented [8]. This study identified a set of proteins that, when considered together, discriminated between patients with IPF and healthy controls. However, this work was limited by the small size of the cohort, thus the generalisability of the observations is uncertain.

In the current study, we leveraged a multicentre cohort of well-characterised patients with IPF to quantify the peripheral blood proteome, determine differential protein expression in patients with IPF versus controls of similar age, sex and smoking history distribution, and identify combinations of proteins that best distinguished patients with IPF from controls. We also examined whether circulating proteins associated with measures of IPF severity.

Methods

Cohorts

The IPF cohort consisted of 300 patients enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry (NCT01915511) [10] between June 2014 and February 2017. The IPF-PRO Registry is a multicentre observational US registry of patients with IPF that was diagnosed or confirmed at the enrolling centre in the past 6 months. IPF was determined by the site investigator according to the 2011 American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Society diagnostic guidelines [11].

Controls were drawn from the Measurement to Understand the Reclassification of Disease of Cabarrus/Kannapolis (MURDOCK) Study, a longitudinal cohort study of adults in North Carolina [12]. Participants considered for inclusion as controls in our study were white and non-Hispanic, aged 60 to 80 years, with an enrolment blood (plasma) sample. Participants were excluded if they had self-reported respiratory disease, cancer, or autoimmune disease at enrolment or during follow-up, were active smokers, had second-hand tobacco exposure, or reported use of respiratory-targeted medication or immunomodulators. Stratified random sampling (stratification on sex and smoking status [ever/never]) was used to select 100 controls.

Assays

Enrolment plasma samples were assayed using an aptamer-based platform encompassing 1305 proteins (SOMAscan, SOMALogic Inc., Boulder, CO). Data were reported in relative fluorescent units (RFU). No values were reported as below the limit of detection/quantification.
Statistical analyses
Descriptive statistics were used to analyse patient characteristics and the expression of each protein in participants with IPF and controls. Linear regression was used to assess whether protein concentrations differed by IPF or control status when considered in a univariate fashion. Specifically, log₂ transformed protein measurements were modelled as a function of group status (IPF versus control) such that the slope coefficient for group status estimated the fold-change (FC) in protein concentration between participants with IPF and controls. The group comparison was characterised by this estimate, its 95% confidence interval and corresponding $p$ Value. $p$ Values were corrected for multiple comparisons using the Benjamini-Hochberg procedure to control the false discovery rate (FDR) at 5%. Differences in protein concentrations between patients with IPF and controls were considered significant if the corrected $p$ Value was < 0.05.

We then employed multivariable classification approaches to understand if a set of proteins could distinguish participants with IPF from controls. Considering all 1305 analytes, highly correlated proteins were identified using pairwise correlation analyses (Pearson correlation coefficient > 0.9) and proteins were removed such that those omitted were those correlated with the most other proteins, resulting in the fewest possible analytes removed ($n = 143$) [13]. The remaining data were Box-Cox transformed, centred and scaled. Prior to model fitting, the data on all 400 participants were randomly divided into training (75%) and test (25%) sets. Two linear and 6 nonlinear models were fit. Linear models were penalised logistic regression (GLMN) and partial least squares (PLS) [13]. Nonlinear models were flexible discriminant analysis (FDA), support vector machines (SVM), K-nearest neighbours (KNN), recursive partitioning - single tree (RPART), random forest (RF), and gradient boosted machine (GBM) [13]. While fitting each model using the training set, 10-fold cross validation was used to choose the optimal tuning parameter based on the area under the receiver operating curve. Operating characteristics including accuracy, kappa, specificity, and sensitivity, as well as positive and negative predictive values were computed in the training set. To evaluate model results, confusion matrices were calculated using a probability cut-off of 0.5 to convert model-predicted probabilities to IPF or control classifications. The model performance characteristics were then computed on the test set. Variable importance measures for each model were assessed and the most important proteins across the models were summarised. We also explored the discrimination of subjects with IPF from controls using a relatively simple linear discrimination function. This function was then refit to the entire 400-participant cohort.

In the IPF cohort, we used univariate linear regression models to determine if circulating proteins were associated with measures of disease severity. Three measures of disease severity were considered: forced vital capacity (FVC) % predicted, diffusion capacity of the lung for carbon monoxide (DLco) % predicted, and the composite physiologic index (CPI), which correlates with the amount of radiographic fibrosis [14]. Each measure was analysed as a continuous variable. As the use of antifibrotic treatment may be related to disease severity, the analyses were repeated adjusting for treatment at enrolment (nintedanib, pirfenidone, neither). Comparisons were considered significant if the FDR-corrected $p$ Value was < 0.05 and there was a ≥ 5 point difference in the disease severity measure per unit change in the log₂RFU for the protein (i.e. the protein had a statistically significant association and a doubling of the protein concentration was associated with a ≥ 5-point difference in the disease severity measure). All statistical analyses were completed in SAS version 9.4 or R version 3.4.2 (‘Short Summer’).

Pathways analyses were performed on proteins found to be significant in the analyses described above using EnrichR [15] based on the Reactome 2016 pathway database [16].

Results
Cohort characteristics
In the IPF cohort ($n = 300$), the median (Q1, Q3) age at enrolment was 70.0 (65.0, 75.0) years, 74% were men, 94% were white and 67% were former smokers (Table 1). The majority of participants (73%) were classified by the investigator as having definite IPF; 54% were recorded in their medical record as taking nintedanib or pirfenidone at the time of enrolment, when the blood sample was drawn. Median (Q1, Q3) FVC % predicted was 69.7 (61.0, 80.2), DLco % predicted was 40.6 (31.7, 49.4) and CPI was 53.5 (46.6, 60.5). In the control cohort ($n = 300$), the median (Q1, Q3) age at enrolment was 66.0 (63.0, 71.5) years, 74% were men, all were white, and 68% were former smokers.

Circulating proteome in patients with IPF versus controls
The concentrations of the 1305 measured proteins are described in Additional file 1: Table S1. Linear regression analyses identified 551 proteins with a level that was significantly different (corrected $p$ Value < 0.05) between patients with IPF and controls. Forty-seven of these proteins had a $|\log_2FC| > 0.585$ (i.e. a 1.5-fold difference in protein concentration between groups), of which 37 occurred at higher levels in patients with IPF than controls (Table 2, Additional file 1: Fig. S1). A total of nine proteins had a $|\log_2FC| > 1$ (Table 2, Additional file 1: Fig. S1).
Among the top proteins with higher circulating levels in the IPF cohort than in controls were several immune-related proteins including chemokine (CC motif) ligand (CCL) 5, 17, 18, 22; chemokine (C-X-C motif) ligand 13 (CXCL13); and complement components C1R, C4A and C4B; as well as extracellular matrix components (including fibronectins), matrix remodelling proteins (including matrix metalloproteinases [MMPs] 1 and 9 and tissue inhibitor of metalloproteinase [TIMP] 3), and proteins important in cell proliferation, adhesion, or motility (such as platelet-derived growth factor [PDGF] subunits A and B, intracellular adhesion molecule 5 [ICAM5]) and secreted protein, acidic and rich in cysteine [SPARC]). Among the top proteins that were observed at lower levels in patients with IPF relative to controls were the matrix remodelling protein stromelysin-1 (MMP3), creatine kinase enzymes B and M, and the advanced glycosylation end products receptor (AGER).

### Table 1 Characteristics of the IPF cohort (N = 300)

| Characteristic | Value |
|---------------|-------|
| Age, years, median (Q1, Q3) | 70 (65, 75) |
| Male, n (%) | 223 (74.3%) |
| Race, n (%) | |
| White | 281 (93.7%) |
| Black/African-American | 8 (2.7%) |
| Asian | 6 (2.0%) |
| Other | 5 (1.7%) |
| Ethnicity (Hispanic or Latino), n (%) | 8 (2.7%) |
| Smoking status, n (%) | |
| Past | 202 (67.3%) |
| Never | 96 (32.0%) |
| Current | 2 (0.7%) |
| Diagnostic criteriaa, n (%) | |
| Definite IPF | 220 (73.3%) |
| Probable IPF | 63 (21.0%) |
| Possible IPF | 17 (5.7%) |
| Emphysema on CT, n (%) | 31 (10.3%) |
| Supplemental oxygen use at rest, n (%) | 59 (20.0%)b |
| Pulmonary function measures, median (Q1, Q3) | |
| FEV1 (L) | 2.2 (1.8, 2.7) |
| FEV1 (% predicted) | 77.4 (68.0, 89.1) |
| FVC (L) | 2.7 (2.2, 3.2) |
| FVC (% predicted) | 69.7 (61.0, 80.2) |
| FEV1/FVC ratio | 74.1 (72.8, 89.6) |
| DLco (mL/min/kPa) | 12.0 (8.6, 14.7) |
| DLco (% predicted) | 40.6 (31.7, 49.4) |
| CPI, median (Q1, Q3) | 53.5 (46.6, 60.5) |
| Antifibrotic drug use, n (%) | |
| Pirfenidone | 106 (35.3%) |
| Nintedanib | 56 (18.7%) |
| Neither pirfenidone or nintedanib | 138 (46.0%) |

**Definition of abbreviations:** CT Computed tomography, CPI Composite physiologic index, DLco Diffusing capacity of the lungs for carbon monoxide, FEV1 Forced expiratory volume in 1 s, FVC Forced vital capacity

*aDetermined by the investigator according to 2011 ATS/ERS/JRS/ALAT diagnostic guidelines [11]*

*bInformation available for 295 patients*

Multiprotein classification approaches to distinguish patients with IPF from controls

We sought to identify a set of proteins that optimally differentiated patients with IPF from controls by fitting models on a training set and a test set. Select performance measures by model in the training set are illustrated in Fig. 1. Six of the eight multivariable classification models evaluated (both linear models [GLMN, PLS] and four non-linear models [FDA, SVM, RF, GBM]) had a good overall ability to distinguish between participants with IPF from controls. Several models made no or minimal classification errors for all iterations of the cross-validation procedure, as indicated by models with an area under the curve (AUC) of 1 with no or minimal variation (Fig. 1A). When the models were applied to the test set, we observed similar results (Fig. 1B). Computed operating characteristics for all models in the test set are shown in Additional file 1: TableS2.

To understand the proteins of importance in distinguishing patients with IPF from controls, we determined the variable importance measures of proteins selected by each multivariable model. Thirteen proteins were designated as among the 10 most influential proteins in at least two of the eight models (Additional file 1: Table S3). A heat map of the expression of these proteins in participants with IPF versus controls is shown in Fig. 2.

As the performance of the linear models was equivalent to that of the more complex non-linear models, we explored the discrimination of IPF using a linear discriminant function with recursive feature elimination. This indicated that the optimal number of proteins to differentiate participants with IPF from controls was nine (Table 3). The linear discriminant analysis considering these nine proteins had an AUC of 0.99. Linear discriminant scores for every participant were calculated by multiplying the protein values for each selected protein by the respective model coefficient (Table 3) and plotted by IPF versus control status. As illustrated in Additional file 1: Fig. S2, the linear discriminant analysis based on these nine proteins distinguished patients with IPF from control subjects with very little overlap.
### Table 2
Top proteins with higher or lower levels in participants with IPF versus controls. Proteins with a $|\log_2 \text{FC}| > 0.585$ (i.e., a > 1.5-fold difference in protein concentration between groups) and a false discovery rate (FDR)-corrected $p$ Value < 0.05 are shown.

| Gene       | Aptamer ID | Protein                                      | $\log_2 \text{FC}$ | $p$ Value | FDR adjusted $p$ Value |
|------------|------------|----------------------------------------------|---------------------|-----------|------------------------|
| Higher levels in participants with IPF versus controls |
| PGAM1      | 3896–5     | Phosphoglycerate mutase 1                    | 1.260               | 9.00E-08  | 9.24E-07               |
| GPD1       | 11,081–1   | Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic | 1.224               | 4.95E-19  | 3.08E-17               |
| THBS1      | 3474–19    | Thrombospondin-1                             | 1.203               | 1.46E-16  | 6.55E-15               |
| WWF        | 3050–7     | von Willebrand factor                        | 1.136               | 3.68E-32  | 1.20E-29               |
| CCL17      | 3519–3     | C-C motif chemokine 17                       | 1.053               | 2.38E-16  | 1.03E-14               |
| BPI        | 4126–22    | Bactericidal permeability-increasing protein | 1.031               | 7.26E-15  | 2.37E-13               |
| OLR1       | 3636–37    | Oxidised low-density lipoprotein receptor 1  | 0.929               | 4.84E-32  | 1.26E-29               |
| CAPG       | 4968–50    | Macrophage-capping protein                   | 0.882               | 1.09E-28  | 1.43E-26               |
| SPARC      | 3043–49    | SPARC                                        | 0.869               | 3.13E-15  | 1.13E-13               |
| FN1        | 4131–72    | Fibronectin                                  | 0.864               | 1.19E-30  | 2.59E-28               |
| PF4        | 2697–7     | Platelet factor 4                            | 0.853               | 7.84E-08  | 8.32E-07               |
| PPBP       | 4544–4     | Connective tissue-activating peptide III     | 0.850               | 2.74E-08  | 3.26E-07               |
| PPBP       | 2790–54    | Neutrophil-activating peptide 2              | 0.844               | 3.23E-08  | 3.73E-07               |
| ICAM5      | 5124–69    | Intercellular adhesion molecule 5            | 0.841               | 4.10E-34  | 1.78E-31               |
| CXCL13     | 3487–32    | C-X-C motif chemokine 13                     | 0.834               | 1.63E-15  | 6.27E-14               |
| PGD        | 4187–49    | 6-phosphogluconate dehydrogenase, decarboxylating | 0.833               | 7.64E-07  | 6.39E-06               |
| C1R        | 3285–23    | Complement C1r subcomponent                  | 0.825               | 3.39E-29  | 5.49E-27               |
| HIST1H1C   | 2987–37    | Histone H1.2                                 | 0.808               | 1.58E-07  | 1.56E-06               |
| MMP9       | 2579–17    | Matrix metalloproteinase-9                   | 0.792               | 4.49E-16  | 1.83E-14               |
| SFTP       | 4414–69    | Pulmonary surfactant-associated protein D    | 0.789               | 1.75E-08  | 2.20E-07               |
| GDF15      | 4374–45    | Growth/differentiation factor 15             | 0.782               | 2.32E-28  | 2.75E-26               |
| S100A9     | 5339–49    | Protein S100-A9                              | 0.778               | 9.08E-18  | 4.74E-16               |
| FN1        | 3434–34    | Fibronectin fragment 3                       | 0.770               | 3.78E-29  | 5.49E-27               |
| PDGFB      | 4149–8     | Platelet-derived growth factor subunit B     | 0.768               | 7.67E-08  | 8.25E-07               |
| CCL18      | 3044–3     | C-C motif chemokine 18                       | 0.734               | 2.31E-29  | 4.31E-27               |
| ANXA6      | 5335–73    | Annexin A6                                   | 0.725               | 3.36E-09  | 4.82E-08               |
| MMP1       | 4924–32    | Matrix metalloproteinase-1                   | 0.712               | 3.92E-11  | 8.25E-10               |
| TIMP3      | 2480–58    | Metalloproteinase inhibitor 3                | 0.690               | 4.04E-10  | 7.32E-09               |
| VAV1       | 5275–28    | Proto-oncogene vav                           | 0.687               | 8.31E-05  | 4.15E-04               |
| HNRNPA2B1  | 5351–52    | Heterogeneous nuclear ribonucleoproteins A2/B1 | 0.683               | 2.27E-12  | 5.69E-11               |
| PDGFA      | 4499–21    | Platelet-derived growth factor subunit A     | 0.665               | 3.05E-08  | 3.55E-07               |
| APP        | 3171–57    | Amyloid-beta A4 protein                      | 0.662               | 1.34E-11  | 2.97E-10               |
| S100A6     | 13,090–17  | Protein S100-A6                              | 0.625               | 4.47E-14  | 1.33E-12               |
| CCL5       | 5480–49    | C-C motif chemokine 5                        | 0.614               | 3.43E-07  | 3.15E-06               |
| C4A C4B    | 2182–54    | Complement C4A and C4B                       | 0.604               | 1.13E-08  | 1.49E-07               |
| CCL22      | 3508–78    | C-C motif chemokine 22                       | 0.599               | 6.96E-18  | 3.95E-16               |
Association between circulating proteome and measures of disease severity in patients with IPF

Using significance criteria of a corrected \( p \) Value < 0.05 and a \( \geq 5 \)-unit difference in disease severity measure per doubling in protein concentration, we identified 14 proteins that were associated with FVC % predicted, 23 with DLco % predicted, and 14 with CPI (Fig. 3). These associations were largely unchanged after adjustment for treatment (nintedanib, pirfenidone, neither) at enrolment (Additional file 1: Tables S4-S6). Four proteins, roundabout homolog-2 (ROBO2), spondin-1 (SPON1), polymeric immunoglobulin receptor (PIGR) and ICAM 5, satisfied both analytic criteria for all three disease severity measures. Each of these proteins were observed at higher levels in patients with more severe disease.

Pathways analysis of proteins associated with presence or severity of IPF

To elucidate potential pathways related to the presence or severity of IPF, we performed a pathways analysis on proteins demonstrated to be significant in the previous analyses. In analyses of the 47 proteins that occurred at different levels in patients with IPF versus controls with an absolute \( > 1.5 \)-fold change and a corrected \( p \) Value < 0.05, we observed a significant enrichment of proteins in pathways related to platelet activation, innate immunity, extracellular matrix organisation, and vascular growth factor signalling (Fig. 4A). The same pathways, plus mechanistically-related pathways and processes, were identified in analyses of the 36 proteins that were significantly correlated with measures of disease severity (Fig. 4B). Additionally, activation and regulation of the complement cascade appeared to be prominent pathways of importance in disease severity.

Discussion

In this comprehensive study using a targeted platform of over 1300 proteins, we identified a distinct circulating proteome associated with IPF. When considered together, nine proteins accurately distinguished patients with IPF from controls who had a similar distribution of age, sex, and smoking status. Further, several proteins were associated with clinical measures of disease severity. When proteins associated with the presence or severity of IPF were considered in pathways analyses, they tended to be found in pathways involved in platelet and haemostatic responses, including vascular growth factor signalling, innate immunity (including innate immunity and the complement cascade), and extracellular matrix organisation.

The majority of proteomic studies in IPF have focussed on the characterisation of protein expression in lung tissue or bronchoalveolar lavage fluid (BALF) [17–21], with only a few studies having quantified the circulating proteome [8, 9]. An additional novel aspect of our analysis was the identification of proteins associated with clinical measures of disease severity, as well as proteins associated with the presence of IPF. In general, the proteins associated with disease severity were distinct from those that distinguished patients with IPF from controls. Though it was expected that proteins associated with CPI would also

Table 2  Top proteins with higher or lower levels in participants with IPF versus controls. Proteins with a \( |\log_{2}FC| > 0.585 \) (i.e. a \( > 1.5 \)-fold difference in protein concentration between groups) and a false discovery rate (FDR)-corrected \( p \) Value < 0.05 are shown (Continued)

| Gene    | Aptamer ID | Protein                                      | \( \log_{2}FC \) | \( p \) Value | FDR adjusted \( p \) Value |
|---------|------------|----------------------------------------------|-----------------|--------------|---------------------------|
| HK2     | 13,130–150 | Hexokinase-2                                 | 0.592           | 2.22E-09     | 3.35E-08                  |
| Lower levels in participants with IPF versus controls |
| MMP3    | 2788–55    | Stromelysin-1                                | −1.343          | 2.77E-36     | 1.81E-33                  |
| CKB, CKM| 3714–49    | Creatine kinase B-type; Creatine kinase M-type| −1.325          | 4.95E-22     | 4.04E-20                  |
| AD5L    | 5023–23    | Adenylosuccinate lyase                        | −1.126          | 2.70E-26     | 2.93E-24                  |
| SHH     | 2743–5     | Sonic hedgehog protein                        | −0.852          | 7.35E-26     | 7.38E-24                  |
| CA6     | 3352–80    | Carbonic anhydrase 6                          | −0.778          | 2.15E-15     | 8.01E-14                  |
| AGER    | 4125–52    | Advanced glycosylation end product-specific receptor| −0.770      | 5.74E-20     | 3.74E-18                  |
| HSPB1   | 11,103–24  | Heat shock protein beta-1                     | −0.734          | 1.46E-05     | 9.18E-05                  |
| TFF1    | 9185–15    | Trefoil factor 1                              | −0.708          | 1.20E-12     | 3.20E-11                  |
| PRKCA   | 2644–11    | Protein kinase C alpha type                   | −0.695          | 3.68E-04     | 1.54E-03                  |
| PRKACA  | 3466–8     | cAMP-dependent protein kinase catalytic subunit alpha| −0.590      | 7.02E-05     | 3.63E-04                  |

\( p \) Values are shown as exponentiated values.
Fig. 1 Operating characteristics of linear and non-linear models to differentiate patients with IPF from controls in training set (a) and receiver operating curve for the test set (b).

FDA, flexible discriminant analysis; GBM, gradient boosted machine; GLMN, penalised logistic regression; KNN, K-nearest neighbours; PLS, partial least squares; RF, random forest; RPART, recursive partitioning; single tree; SVM, support vector machines.
be associated with DLco or FVC, given that these measures are used in the CPI calculation, we observed that only four proteins (ROBO2, SPON1, PIGR, ICAM5) were associated with all three disease severity measures.

Our observation related to expression of circulating PIGR, a transmembrane glycoprotein important in immunoglobulin A transport across mucosal epithelial cells, is particularly intriguing, as prior work has demonstrated that the lungs of patients with IPF have ectopic expression of PIGR within areas of type 2 alveolar cell hyperplasia [22]. Moreover, PIGR-deficient mice demonstrated attenuated lung fibrosis after bleomycin treatment compared with wild-type mice [22]. Others have demonstrated that PIGR is upregulated by cytokines induced by innate immune activation and have implicated PIGR as a bridge between innate and adaptive immune responses [23], responses which we found to be enriched in pathways analyses of proteins associated...
with disease severity. While the other three proteins associated with all three disease severity measures have not been well characterised in lung fibrosis, ROBO2 has been demonstrated to be overexpressed in a murine model of toxin-induced liver fibrosis, where it localised on the surface of hepatic stellate cells within fibrotic septae. Moreover, the interaction between ROBO2 and its ligand (slit guidance ligand 2) promoted fibrogenic activity within stellate cells [24].

In prior work, an aptamer-based proteomic approach similar to that used in our analysis was used to quantify 1129 circulating proteins in 60 patients with IPF versus 21 healthy controls of older mean age who were lifetime non-smokers. Consistent with our observations, higher levels of complement C1r subcomponent, complement C4, fibronectin, ICAM 5, thrombospondin 1, and MMP1 were observed in the IPF cohort [8]. However, many of the proteins found to have lower levels in patients with IPF than in controls in this previous study were observed at higher levels in patients with IPF than controls in our study, including MMP9, S100A9, and surfactant protein D, for which other literature supports increased expression in IPF [8, 25–29]. The factors accounting for these divergent observations are likely multifactorial, and may include the types of assays used, technical aspects of the aptamer-based assay, differences in disease severity between the groups with IPF, or differences between the control groups.

While the peripheral blood proteome may not fully reflect intrapulmonary changes, several of our findings are consistent with those of proteomic studies of BALF or lung tissue. A study using mass spectrometry-based

### Table 3

Nine proteins that optimally differentiated patients with IPF from control participants. Proteins selected by the linear discriminant function with recursive feature elimination and the respective model coefficient

| Gene     | Aptamer ID | Protein                        | Model coefficienta |
|----------|------------|--------------------------------|--------------------|
| APOA1    | 2750-3     | Apolipoprotein A-1             | 0.38               |
| C1R      | 3285-23    | Complement C1r subcomponent    | −0.41              |
| MMP3     | 2788-55    | Stromelysin-1                  | −0.30              |
| SFN      | 4829-43    | 14-3-3 protein sigma           | 0.43               |
| CCL18    | 3044-3     | C-C motif chemokine 18         | 0.36               |
| ICAM5    | 5124-69    | Intercellular adhesion molecule 5 | −0.06             |
| SHH      | 2743-5     | Sonic hedgehog protein         | 0.46               |
| OLR1     | 3636-37    | Oxidised low-density lipoprotein receptor 1 | −0.32             |
| CAPG     | 4968-50    | Macrophage-capping protein     | 0.28               |

aThe sign of the coefficient indicates whether the subject’s linear discriminant analysis score increases or decreases as values of the protein change. Higher scores are associated with IPF, as opposed to control, status.
Fig. 4 (See legend on next page.)
proteomics of BALF demonstrated a 3-fold increase in CCL18 and protein S100A9 in patients with IPF compared with controls [18]. Another proteomic study of BALF from patients with fibrotic diseases, including IPF, demonstrated increased expression of S100A6 [20]. Several proteins observed at higher or lower levels in patients with IPF in our study were consistent with observations from a study that performed unbiased proteomics on lung tissue samples from patients with fibrosing lung disease. For example, both studies demonstrated higher levels of CCL13 and lower levels of AGER compared with controls [17]. These observations suggest that blood-based protein analysis may be a useful tool to phenotype patients with IPF and facilitate monitoring of disease progression. Consistent with this idea, Maher et al. quantified 123 circulating proteins in patients with IPF and identified a new IPF-associated protein, cancer antigen-125 protein, rising levels of which were associated with the risk of disease progression and mortality [29]. The newly identified IPF-associated circulating proteins identified in our analyses expand the pool of candidate biomarkers for further evaluation in relation to clinically relevant outcomes.

Our results support the importance of circulating proteins relevant to extracellular matrix remodelling in patients with IPF. Notably several extracellular matrix glycoproteins, MMPs 1 and 9, and the MMP inhibitor TIMP3 were present at higher levels in patients with IPF relative to controls. These data are of interest in view of prior work by Jenkins et al. demonstrating that circulating levels of protein fragments generated by MMP activity are increased in patients with IPF relative to healthy controls and may associate with disease progression [30]. Although the majority of our data with regard to extracellular matrix remodelling protein expression are consistent with prior work, we note a particular discordance between our results and those of previous studies related to MMP3. High MMP3 levels have been reported in lung tissue from patients with IPF, and genetic deletion of MMP3 in mice abrogates bleomycin-induced pulmonary fibrosis [31, 32]. In contrast to these observations, in our cohort, of all the proteins with lower levels in patients with IPF than in controls, MMP3 showed the strongest association. Given that MMP3 was selected as a protein of importance in multivariable models distinguishing patients with IPF from controls, including the linear discriminant analysis, we examined the sensitivity of this model to the exclusion of MMP3. When the analysis was performed without MMP3 in the pool of analytes available for model selection, the optimal number of proteins to differentiate participants with IPF from controls was also nine, with adenylosuccinate lyase filling the final position and the remaining markers chosen in the same order. The linear discriminant analysis considering these nine proteins also had an AUC of 0.99 (data not shown).

Our study has several strengths, including the multicentre nature of the IPF cohort and the inclusion of control participants of comparable age, sex and smoking distribution. However, we acknowledge some inherent limitations. First, we acknowledge that our cohort is a US-based population of predominantly white patients, thus broader generalisability to other populations of patients with IPF is uncertain. Additionally, although we characterised a broad array of proteins, our approach was targeted rather than discovery-based, so proteins of potential importance could have been missed if not included on our platform. Finally, we acknowledge that an aptamer-based approach to protein detection and quantification does not always yield results that are reproducible when using ELISA-based approaches. This may in fact explain the differences between previous studies and our results with regard to MMP3. Thus, the proteins we identified as of interest in our study need to be validated, both from a technical and a clinical viewpoint. In particular, the association of the circulating proteins identified herein with clinical measures of IPF severity warrants validation.

**Conclusion**

The results of this study add to the evidence suggesting that circulating proteins are likely to hold value in the diagnostic approach to IPF. Additionally, these data indicate that profiling of circulating proteins may provide insights into biological pathways underlying the development of IPF or contributing to disease severity. Validation of candidate proteins will be necessary, as will extension of these analyses to examine the association of the circulating proteome with clinical outcomes. Rich longitudinal data collection through the IPF-PRO Registry, including serial pulmonary function measures, hospitalisation data, and information on vital status, will support these analyses and further the goal of improving the diagnosis and management of IPF.
Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s12931-019-1190-z.

Additional file 1: Figure S1. Differential levels of circulating proteins in participants with IPF versus controls. Volcano plot of the Log2fold change in means by log10 of the corrected p Value for each protein. The horizontal line indicates the threshold for statistical significance. Figure S2. Histogram of the linear discriminant scores for each participant in the IPF and control cohort. Table S1. Summary statistics for all 1305 proteins assayed across the IPF and control cohorts. Protein data are reported in relative fluorescent units. Table S2. Operating characteristics of all models in the test set for the IPF versus control multivariable modelling. Table S3. Proteins designated as among the most influential in at least two of the eight multivariable models. Table S4. Proteins significantly associated with FVC % predicted (unadjusted and adjusted for anti-fibrotic treatment). Table S5. Proteins significantly associated with DLco % predicted (unadjusted and adjusted for anti-fibrotic treatment). Table S6. Proteins significantly associated with composite physiologic index (unadjusted and adjusted for anti-fibrotic treatment).

Abbreviations

AGER: Advanced glycosylation end products receptor; AUC: Area under the curve; BALF: Bronchoalveolar lavage fluid; CCL: Chemokine ligand; CPI: Composite physiologic index; DLco: Diffusion capacity of the lung for carbon monoxide; ELISA: Enzyme-linked immunosorbent assay; F: Fold-change; FDA: Flexible discriminant analysis; FDR: False discovery rate; FVC: Forced vital capacity; GBM: Gradient boosted machine; GLMN: Penalised logistic regression; ICAMS: Intracellular adhesion molecule 5; IPF: Idiopathic pulmonary fibrosis; IPF-PRO Registry: Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry; KNN: K-nearest neighbour; MMP: Matrix metalloproteinase; MMP3: Matrix remodelling protein stromelysin-1; MURDOCK: Measurement to Understand the Reclassification of Disease of Cabarrus/Kannapolis Study; PDGF: Platelet-derived growth factor; PIGR: Polymeric immunoglobulin receptor; PLS: Partial least squares; RF: Random forest; RFU: Relative fluorescent unit; ROBO2: Roundabout homolog-2; RPART: Recursive partitioning - single tree; SPARC: Secreted protein acidic and rich in cysteine; SPON1: Spondin-1; SVM: Support vector machine; TIMP: Tissue inhibitor of metalloproteinase

Acknowledgements

The authors acknowledge the IPF-PRO Registry participants and principal investigators: Wael Asi, Renovatio Clinical, The Woodlands, TX; Albert Baker, Lynchburg Pulmonary Associates, Lynchburg, VA; Scott Beegle, Albany Medical Center, Albany, NY; John A. Belperio, University of California Los Angeles, Los Angeles, CA; Tracy Bey, University of Miami, Miami, FL; Siddhartha Bhattacharyya, Southern Illinois University School of Medicine, Springfield, IL; Todd Bresnahan, University of Chicago, Chicago, IL; Shelley Burns, Novartis, East Hanover, NJ; John Cao, University of California, San Francisco, CA; Patricia Caraballo, University of Pennsylvania, Philadelphia, PA; Marieli Carvalho, Brigham and Women’s Hospital, Boston, MA; Snehal Patel, Beijing Pulmonary & Critical Care Institute, China; Todd Todd; Vascular Medicine Institute, Washington University, St. Louis, MO; Marla Coker, University of Kansas Medical Center, Kansas City, MO; Michael Cohen, Beth Israel Medical Center, New York, NY; Neil Connolly, University of Virginia, Charlottesville, VA; Cheryl Cotterman, University of Nebraska Medical Center, Omaha, NE; Stuart Corrin, University of North Carolina, Chapel Hill, NC; Ravi Cullum, University of Sheffield, Sheffield, UK; Liana David, University of Arizona, Tucson, AZ; Timothy P. Whelan, Medical University of South Carolina, Charleston, SC; and the late Philip Eleuterio, University of Arizona, Tucson, AZ; Anthony Giovanniello, University of Miami, Miami, FL; Robert Gottlieb, New York University, New York, NY; Todd Gross, University of Washington, Seattle, WA; Michael Gross, University of Wisconsin, Madison, WI; Joseph Handmade, Mayo Clinic, Rochester, MN; Justin Hall, University of Michigan, Ann Arbor, MI; Marilyn Glassberg, University of Miami, Miami, FL; Mindu Gulati, Yale School of Medicine, New Haven, CT; Kalpalatha Gunupalli, Baylor College of Medicine, Houston, TX; Nishant Gupta, University of Cincinnati Medical Center, Cincinnati, OH; Amy Hajari Case, Piedmont Healthcare, Austell, GA; Ananta Harihara, Emory University, Atlanta, GA; David Hotchin, The Oregon Clinic, Portland, OR; Tristan Huie, National Jewish Hospital, Denver, CO; Robert Kaner, Weill Cornell Medical College, New York, NY; Hyun Kim, University of Minnesota, Minneapolis, MN; Maryl Kreider, University of Pennsylvania, Philadelphia, PA; Lisa Lancaster, Vanderbilt University, Nashville, TN; Joseph Laskey, Tulane University, New Orleans, LA; David Lederer, Columbia University Medical Center/New York Presbyterian Hospital, New York, NY; Doug Lee, Wilkinson Health and PMG Research, Waltham, MA; Daniel Lilley, St. Louis University, St. Louis, MO; Rishi Raj, Stanford University, Stanford, CA; Murali Ramaswamy, Pulmonix LLC, Greensboro, NC; Tonya Russell, Washington University, St. Louis, MO; Paul Sachs, Pulmonary Associates of Stamford, Stamford, CT; Zeenat Safdar, Houston Methodist Lung Center, Houston, TX; Barry Sigal,alem Chest and Southeastern Clinical Research Center, Winston Salem, NC; Leann Silhan, UT Southwestern Medical Center, Dallas, TX; Mary Strek, University of Chicago, Chicago, IL; Sally Sullivan, University of Louisville, Louisville, KY; Jeremy Tabak, South Miami Hospital, South Miami, FL; Rajat Walia, St. Joseph’s Hospital, Phoenix, AZ; Timothy P. Whelan, Medical University of South Carolina, Charleston, SC. Writing support was provided by Elizabeth Ng, BSc and Wendy Morris, MSc of FlesihmanHillard Fishburn, London, UK, which was contracted and funded by Boehringer Ingelheim Pharmaceuticals, Inc. The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations.

Authors’ contributions

All authors contributed to the design of the study. JLT, MG, HH, JRoman, LKN, KRF, TL, CH, IN, JAB and SMP contributed to the acquisition of data. MLN, RO, KD, YL, RV, JRoy, RS and BS developed the analytic plan and contributed to the data analysis. All authors contributed to data interpretation. JLT drafted the manuscript. All authors critically revised the manuscript and approved the final version for submission.

Funding

The IPF-PRO™ Registry is funded by Boehringer Ingelheim Pharmaceuticals, Inc. and coordinated by the Duke Clinical Research Institute. This study also used biosample resources acquired through the MURDOCK Study, which acknowledges funding from the David H Murdock Institute for Business & Culture and Duke University’s CTSA grant (UL1TR001117) from the National Institutes of Health’s National Center for Advancing Translational Sciences.

Availability of data and materials

All data relevant to the study are included in the article or uploaded as supplementary information.

Ethics approval and consent to participate

The IPF-PRO Registry was approved by the Duke University Institutional Review Board (Pro00046131). The IPF-PRO Registry protocol was also approved by the relevant Institutional Review Boards and/or local Independent Ethics Committees prior to patient enrolment at each site listed in the Acknowledgements and all patients provided informed consent. The MURDOCK Study Community Registry and Biorepository was approved by the Duke University Institutional Review Board, and all participants provided written informed consent.

Consent for publication

Not applicable.

Competing interests

JLT, MLN, RO, LKN and SMP are employees of the Duke Clinical Research Institute, which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc. to coordinate the IPF-PRO Registry. MG reports personal fees, non-financial support, and other support from the France Foundation; grants, non-financial support and other support from Boehringer Ingelheim and the Pulmonary Fibrosis Foundation; and personal fees from Genentech. HH is on a speaker panel for Boehringer Ingelheim. JRoman reports grants and personal fees from Boehringer Ingelheim; and grants from Genentech, the Department of Veterans Affairs, and the National Institutes of Health. Until the end of 2017, JRoman served on the board of the American Lung Association - Midland States, and chaired the American Thoracic Society Committee on Health Equality and Inclusion. KRF reports grants and personal fees from Boehringer Ingelheim and Roche/Genentech; and personal fees from FibroGen, Sanofi Genzyme, and Veracyte. JRoy is an employee of Staburo GmbH, which was contracted by Boehringer Ingelheim for this work. In reports personal fees from Boehringer Ingelheim, Genentech and ImmuneWorks. JAB has no disclosures. KD, RV, YL, RS, BS, CH and TBL are employees of Boehringer Ingelheim.
Author details

1Duke Clinical Research Institute, Durham, NC, USA. 2Duke University Medical Center, Durham, NC, USA. 3Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA. 4 Yale School of Medicine, New Haven, CT, USA. 5Houston Methodist Hospital, Houston, TX, USA. 6Jane and Leonard Nerman Respiratory Institute, Philadelphia, PA, USA. 7Duke Clinical & Translational Science Institute, Durham, NC, USA. 8Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA. 9Staburo GmbH, Munich, Germany. 10Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. 11University of Virginia, Charlottesville, Virginia, USA. 12David Geffen School of Medicine at UCLA, California, Los Angeles, USA.

Received: 19 July 2019 Accepted: 20 September 2019
Published online: 22 October 2019

References

1. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44.
2. Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis. A Fleischer society white paper. Lancet Respir Med. 2018;6:138–53.
3. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.
4. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. Phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.
5. Vij R, Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res. 2012;159:218–27.
6. Bowler RP, Wendt CH, Fessler MB, et al. New strategies and challenges in lung proteomics and metabolomics. An official American Thoracic Society workshop report. Ann Am Thorac Soc. 2017;14:1721–43.
7. Norman KC, Moore BB, Arnold KB, O'Dwyer DN. Proteomics: clinical and research applications in respiratory diseases. Respirio. 2018;23:993–1003.
8. O'Dwyer DN, Norman KC, Xia M, et al. The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes. Sci Rep. 2017;7:46560.
9. Niu R, Liu Y, Zhang Y, et al. iTRAQ-based proteomics reveals novel biomarkers for idiopathic pulmonary fibrosis. PLoS One. 2017;12:e0170741.
10. O'Brien EC, Durham MT, Gammeter V, et al. Rationale for and design of the idiopathic pulmonary fibrosis–PROspective outcomes (IPF-PRO) registry. BMJ Open Respir Res. 2016;3:e000108.
11. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.
12. Bhattacharya S, Dunham AA, Comish NA, et al. The measurement to understand reclassification of disease of Cabarrus/Kannapolis (MURDOCK) study community registry and biorepository. Am J Transl Res. 2012;4:458–70.
13. Kühn M, Johnson K. Applied predictive modeling. New York: Springer-Verlag; 2013.
14. Wells AJ, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167:962–9.
15. Kuleshov MV, Jones MR, Rouillard AD, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90–7.
16. Fabregat A, Sidtopoulos K, Garapati P, et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 2016;44:D481–7.
17. Schiller HB, Mayr CH, Leuschner G, et al. Deep proteome profiling reveals common prevalence of M2B1-positive plasma B cells in human lung and skin fibrosis. Am J Respir Crit Care Med. 2017;196:1298–310.
18. Foster MW, Morrison LD, Todd JL, et al. Quantitative proteomics of bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. J Proteome Res. 2015;14:1238–49.
19. Korfel M, von der Beck D, Henneke I, et al. Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP) and organ donors. J Proteomics. 2013;85:109–28.
20. Land C, Bargagli E, Bianchi L, et al. Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis. J Proteomics. 2013;83:60–75.
21. Tian Y, Li H, Gao Y, et al. Quantitative proteomic characterization of lung tissue in idiopathic pulmonary fibrosis. Clin Proteomics. 2019;166.
22. Plante-Bordeneuve T, Pilette C, Yakoub Y, Lecocq M, Huaux F, Froidure A. Epithelial pIgR: a new player in idiopathic pulmonary fibrosis? Eur Respir J. 2018;52(suppl 62):PA2174.
23. Kaetzel C. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol Rev. 2005;206:83–99.
24. Zeng Z, Wu Y, Cao Y, et al. Slit2-Robo2 signaling modulates the fibrogenic activity and migration of hepatic stellate cells. Life Sci. 2018;203:39–47.
25. Greene KE, King TE Jr, Kuroki Y, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002;19:439–47.
26. Henry MT, McMahon K, Mackarel AJ, et al. Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF. Eur Respir J. 2002;20:1220–7.
27. Rosas IO, Richards TJ, Korishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008;5:e93.
28. Hara A, Sakamoto N, Ishimatsu Y, et al. S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis. Respir Med. 2012;106:571–80.
29. Maher TM, Oballa E, Simpson JK, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILe cohort study. Lancet Respir Med. 2017;5:946–55.
30. Jenkins RG, Simpson JK, Saini G, et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILe study. Lancet Respir Med. 2015;3:462–72.
31. McKeown S, Richter AG, O’Kane C, McAuley DF, Thickett DR. MMP expression and abnormal lung permeability are important determinants of outcome in IPF. Eur Respir J. 2009;33:77–84.
32. Yamashita CM, Dolgonos L, Zemans RL, et al. Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis. Am J Pathol. 2011;179:1733–45.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.